{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:55:16Z","timestamp":1791456916485,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40271-025-00798-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:26:30Z","timestamp":1769012790000},"page":"481-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment"],"prefix":"10.1007","volume":"19","author":[{"given":"Kathleen F.","family":"Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yarlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Ruggles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cannon","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Vass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"6","key":"798_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100792","volume":"16","author":"J Raasch","year":"2023","unstructured":"Raasch J, Glaum MC, O\u2019Connor M. The multifactorial impact of receiving a hereditary angioedema diagnosis. World Allergy Organ J. 2023;16(6):100792. https:\/\/doi.org\/10.1016\/j.waojou.2023.100792.","journal-title":"World Allergy Organ J"},{"issue":"4","key":"798_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaip.2023.12.025","volume":"12","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Bordone L, Revenko A, Newman KB, Cohn DM. Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema. J Allergy Clin Immunol Pract. 2024;12(4):911\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2023.12.025.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"798_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","volume":"40","author":"ES Sinnathamby","year":"2023","unstructured":"Sinnathamby ES, Issa PP, Roberts L, Norwood H, Malone K, Vemulapalli H, et al. Hereditary angioedema: diagnosis, clinical implications, and pathophysiology. Adv Ther. 2023;40(3):814\u201327. https:\/\/doi.org\/10.1007\/s12325-022-02401-0.","journal-title":"Adv Ther"},{"key":"798_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/TCRM.S86293","volume":"12","author":"MP Henao","year":"2016","unstructured":"Henao MP, Kraschnewski JL, Kelbel T, Craig TJ. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016;12:701\u201311. https:\/\/doi.org\/10.2147\/TCRM.S86293.","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"798_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s12325-012-0053-5","volume":"29","author":"MJ Prematta","year":"2012","unstructured":"Prematta MJ, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther. 2012;29(10):913\u201322. https:\/\/doi.org\/10.1007\/s12325-012-0053-5.","journal-title":"Adv Ther"},{"issue":"3","key":"798_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/lio2.555","volume":"6","author":"M Rosi-Schumacher","year":"2021","unstructured":"Rosi-Schumacher M, Shah SJ, Craig T, Goyal N. Clinical manifestations of hereditary angioedema and a systematic review of treatment options. Laryngoscope Investig Otolaryngol. 2021;6(3):394\u2013403. https:\/\/doi.org\/10.1002\/lio2.555.","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"9","key":"798_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092023","volume":"10","author":"R Santacroce","year":"2021","unstructured":"Santacroce R, D\u2019Andrea G, Maffione AB, Margaglione M, d\u2019Apolito M. The genetics of hereditary angioedema: a review. J Clin Med. 2021;10(9):2023. https:\/\/doi.org\/10.3390\/jcm10092023.","journal-title":"J Clin Med"},{"issue":"8","key":"798_CR8","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jaip.2023.04.035","volume":"11","author":"PFK Yong","year":"2023","unstructured":"Yong PFK, Coulter T, El-Shanawany T, Garcez T, Hackett S, Jain R, et al. A national survey of hereditary angioedema and acquired C1 inhibitor deficiency in the United Kingdom. J Allergy Clin Immunol Pract. 2023;11(8):2476\u201383. https:\/\/doi.org\/10.1016\/j.jaip.2023.04.035.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"798_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100812","volume":"16","author":"S Nieto","year":"2023","unstructured":"Nieto S, Madrigal I, Contreras F, Vargas ME. Real-world experience of hereditary angioedema (HAE) in Mexico: a mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns. World Allergy Organ J. 2023;16(9):100812. https:\/\/doi.org\/10.1016\/j.waojou.2023.100812.","journal-title":"World Allergy Organ J"},{"issue":"8","key":"798_CR10","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1016\/j.jaip.2023.01.023","volume":"11","author":"MA Riedl","year":"2023","unstructured":"Riedl MA, Danese M, Danese S, Ulloa J, Maetzel A, Audhya PK. Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns. J Allergy Clin Immunol Pract. 2023;11(8):2450-6.e6. https:\/\/doi.org\/10.1016\/j.jaip.2023.01.023.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"798_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00537-2","volume":"17","author":"K Bork","year":"2021","unstructured":"Bork K, Anderson JT, Caballero T, Craig T, Johnston DT, Li HH, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17(1):40. https:\/\/doi.org\/10.1186\/s13223-021-00537-2.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"798_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","volume":"153","author":"D Honda","year":"2024","unstructured":"Honda D, Li PH, Jindal AK, Katelaris CH, Zhi YX, Thong BY, et al. Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: a focus on the Asia-Pacific region. J Allergy Clin Immunol. 2024;153(1):42\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2023.09.039.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"798_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/ced\/llad428","volume":"49","author":"A Kumar Jindal","year":"2024","unstructured":"Kumar Jindal A, Basu S, Tyagi R, Barman P, Sil A, Chawla S, et al. Delay in diagnosis is the most important proximate reason for mortality in hereditary angio-oedema: our experience at Chandigarh, India. Clin Exp Dermatol. 2024;49(4):368\u201374. https:\/\/doi.org\/10.1093\/ced\/llad428.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"798_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600\u20137. https:\/\/doi.org\/10.1016\/j.anai.2020.02.018.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"798_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100758","volume":"16","author":"HJ Chong-Neto","year":"2023","unstructured":"Chong-Neto HJ. A narrative review of recent literature of the quality of life in hereditary angioedema patients. World Allergy Organ J. 2023;16(3):100758. https:\/\/doi.org\/10.1016\/j.waojou.2023.100758.","journal-title":"World Allergy Organ J"},{"issue":"7","key":"798_CR16","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update. Allergy. 2022;77(7):1961\u201390. https:\/\/doi.org\/10.1111\/all.15214.","journal-title":"Allergy"},{"issue":"1","key":"798_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-50.e3. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"798_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/cei\/uxae020","volume":"217","author":"PFK Yong","year":"2024","unstructured":"Yong PFK, Annals R, Diwakar L, Elkhalifa S, Gompels M, Jain R, et al. Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus. Clin Exp Immunol. 2024;217(1):109\u201316. https:\/\/doi.org\/10.1093\/cei\/uxae020.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"798_CR19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","volume":"148","author":"M Maurer","year":"2021","unstructured":"Maurer M, Aygoren-Pursun E, Banerji A, Bernstein JA, Balle Boysen H, Busse PJ, et al. Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. J Allergy Clin Immunol. 2021;148(6):1526\u201332. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.016.","journal-title":"J Allergy Clin Immunol"},{"key":"798_CR20","unstructured":"US HAEA. US Hereditary Angiodema Association. Approved HAE treatments. 2025. https:\/\/www.haea.org\/pages\/p\/treatments. Accessed 15 Jan 2025."},{"issue":"1","key":"798_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00795-2","volume":"19","author":"J Mendivil","year":"2023","unstructured":"Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, et al. A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis. Allergy Asthma Clin Immunol. 2023;19(1):48. https:\/\/doi.org\/10.1186\/s13223-023-00795-2.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"798_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2500\/aap.2024.45.230073","volume":"45","author":"R Tachdjian","year":"2024","unstructured":"Tachdjian R, Savic S, Fridman M, Frade JP, Fasehun M, Audhya PK. Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks. Allergy Asthma Proc. 2024;45(1):37\u201343. https:\/\/doi.org\/10.2500\/aap.2024.45.230073.","journal-title":"Allergy Asthma Proc"},{"issue":"11","key":"798_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/1346-8138.16909","volume":"50","author":"M Hide","year":"2023","unstructured":"Hide M, Ohsawa I, Nurse C, Yu M. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: a phase 3 multicenter, open-label study. J Dermatol. 2023;50(11):1381\u201391. https:\/\/doi.org\/10.1111\/1346-8138.16909. (Investigators SHPT).","journal-title":"J Dermatol"},{"key":"798_CR24","unstructured":"Berotralstat PI. BioCryst Pharmaceuticals, Inc. Highlights of prescribing information. December 2020. Avaiilable from: ttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214094s000lbl.pdf. Accessed 5 Feb 2025."},{"key":"798_CR25","unstructured":"BioCryst Pharmaceuticals Inc. Canadian Agency for Drugs and Technologies in Health. Berotralstat (Orladeyo): CADTH reimbursement review: therapeutic area: hereditary angioedema (HAE). 2023. Available from: [https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596626\/. Accessed 15 Jan 2025."},{"issue":"1","key":"798_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","volume":"148","author":"B Zuraw","year":"2021","unstructured":"Zuraw B, Lumry WR, Johnston DT, Aygoren-Pursun E, Banerji A, Bernstein JA, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164-72.e9. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.015.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"798_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Tachdjian R, Lumry WR, Craig T, Karakaya G, Gelincik A, et al. Efficacy and safety of donidalorsen for hereditary angioedema. N Engl J Med. 2024;391(1):21\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2402478.","journal-title":"N Engl J Med"},{"issue":"6","key":"798_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/alr.22764","volume":"11","author":"AF Burnette","year":"2021","unstructured":"Burnette AF. Informed decision-making in hereditary angioedema prophylaxis. Int Forum Allergy Rhinol. 2021;11(6):965\u20136. https:\/\/doi.org\/10.1002\/alr.22764.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"9","key":"798_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883\u2013902. https:\/\/doi.org\/10.1007\/s40273-014-0170-x.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"798_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"EW de Bekker-Grob","year":"2012","unstructured":"de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145\u201372. https:\/\/doi.org\/10.1002\/hec.1697.","journal-title":"Health Econ"},{"issue":"4","key":"798_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, et al. Conjoint analysis applications in health: how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. The Patient: Patient-Centered Outcomes Research. 2010;3(4):249\u201356. https:\/\/doi.org\/10.2165\/11539650-000000000-00000.","journal-title":"The Patient: Patient-Centered Outcomes Research"},{"key":"798_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-4020-5753-3_1","volume-title":"Using discrete choice experiments to value health and health care","author":"M Ryan","year":"2008","unstructured":"Ryan M, Gerad K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2008. p. 13\u201346. https:\/\/doi.org\/10.1007\/978-1-4020-5753-3_1."},{"issue":"2","key":"798_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present, and future. Pharmacoeconomics. 2019;37(2):201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"798_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40271-024-00705-7","volume":"18","author":"FR Johnson","year":"2025","unstructured":"Johnson FR, Adamowicz W, Groothuis-Oudshoorn C. What can discrete-choice experiments tell us about patient preferences? An introduction to quantitative analysis of choice data. Patient. 2025;18(5):425\u201340. https:\/\/doi.org\/10.1007\/s40271-024-00705-7.","journal-title":"Patient"},{"issue":"5","key":"798_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40271-024-00696-5","volume":"18","author":"JA Whitty","year":"2025","unstructured":"Whitty JA, Lancsar E, De Abreu Lourenco R, Howard K, Stolk EA. Putting the choice in choice tasks: incorporating preference elicitation tasks in health preference research. Patient. 2025;18(5):415\u201323. https:\/\/doi.org\/10.1007\/s40271-024-00696-5.","journal-title":"Patient"},{"issue":"4","key":"798_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40271-024-00695-6","volume":"18","author":"S Ozdemir","year":"2025","unstructured":"Ozdemir S, Quaife M, Mohamed AF, Norman R. An overview of data collection in health preference research. Patient. 2025;18(4):303\u201315. https:\/\/doi.org\/10.1007\/s40271-024-00695-6.","journal-title":"Patient"},{"issue":"2","key":"798_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40271-024-00672-z","volume":"17","author":"NB Campoamor","year":"2024","unstructured":"Campoamor NB, Guerrini CJ, Brooks WB, Bridges JFP, Crossnohere NL. Pretesting discrete-choice experiments: a guide for researchers. Patient. 2024;17(2):109\u201320. https:\/\/doi.org\/10.1007\/s40271-024-00672-z.","journal-title":"Patient"},{"issue":"4","key":"798_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40271-024-00673-y","volume":"18","author":"AC Muhlbacher","year":"2025","unstructured":"Muhlbacher AC, de Bekker-Grob EW, Rivero-Arias O, Levitan B, Vass C. How to present a decision object in health preference research: attributes and levels, the decision model, and the descriptive framework. Patient. 2025;18(4):291\u2013302. https:\/\/doi.org\/10.1007\/s40271-024-00673-y.","journal-title":"Patient"},{"issue":"3","key":"798_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40271-023-00671-6","volume":"18","author":"DA Marshall","year":"2025","unstructured":"Marshall DA, Veldwijk J, Janssen EM, Reed SD. Stated-preference survey design and testing in health applications. Patient. 2025;18(3):187\u201397. https:\/\/doi.org\/10.1007\/s40271-023-00671-6.","journal-title":"Patient"},{"issue":"3","key":"798_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to measuring and interpreting attribute importance. The Patient Patient-Cent Outcomes Res. 2019;12(3):287\u201395. https:\/\/doi.org\/10.1007\/s40271-019-00360-3.","journal-title":"The Patient Patient-Cent Outcomes Res"},{"key":"798_CR41","unstructured":"Haegarda PI. CSL Behring GmbH. Highlights of prescribing information. January 2022. Available from:phttps:\/\/www.haegarda.com\/prescribing-information. Accessed 15 Jan 2025."},{"key":"798_CR42","unstructured":"Orladeyo PI. BioCryst Pharmaceuticals, Inc. Highlights of prescribing information. October 2024. Available from: https:\/\/www.biocryst.com\/wp-content\/uploads\/ORLADEYO_USPI.pdf. Accessed 15 Jan 2025."},{"key":"798_CR43","unstructured":"Takhzyro PI. Takeda Pharmaceuticals U.S.A., Inc. Highlights of prescribing information. February 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761090s010lbl.pdf. Accessed 15 Jan 2025."},{"issue":"11","key":"798_CR44","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","volume":"386","author":"LM Fijen","year":"2022","unstructured":"Fijen LM, Riedl MA, Bordone L, Bernstein JA, Raasch J, Tachdjian R, et al. Inhibition of prekallikrein for hereditary angioedema. N Engl J Med. 2022;386(11):1026\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2109329.","journal-title":"N Engl J Med"},{"issue":"10382","key":"798_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10382):1079\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)00350-1.","journal-title":"Lancet"},{"issue":"20","key":"798_CR46","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108\u201321. https:\/\/doi.org\/10.1001\/jama.2018.16773.","journal-title":"JAMA"},{"key":"798_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0362-1","volume":"15","author":"HH Li","year":"2019","unstructured":"Li HH, Zuraw B, Longhurst HJ, Cicardi M, Bork K, Baker J, et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. Allergy Asthma Clin Immunol. 2019;15:49. https:\/\/doi.org\/10.1186\/s13223-019-0362-1.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"798_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/14712598.2020.1724280","volume":"20","author":"H Longhurst","year":"2020","unstructured":"Longhurst H, Farkas H. Biological therapy in hereditary angioedema: transformation of a rare disease. Expert Opin Biol Ther. 2020;20(5):493\u2013501. https:\/\/doi.org\/10.1080\/14712598.2020.1724280.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"798_CR49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.2500\/aap.2018.39.4123","volume":"39","author":"A Banerji","year":"2018","unstructured":"Banerji A, Li Y, Busse P, Riedl MA, Holtzman NS, Li HH, et al. Hereditary angioedema from the patient\u2019s perspective: a follow-up patient survey. Allergy Asthma Proc. 2018;39(3):212\u201323. https:\/\/doi.org\/10.2500\/aap.2018.39.4123.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"798_CR50","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2340\/00015555-2014","volume":"95","author":"A Bygum","year":"2015","unstructured":"Bygum A, Aygoren-Pursun E, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. Burden of illness in hereditary angioedema: a conceptual model. Acta Derm Venereol. 2015;95(6):706\u201310. https:\/\/doi.org\/10.2340\/00015555-2014.","journal-title":"Acta Derm Venereol"},{"key":"798_CR51","unstructured":"ClinicalTrials.gov. NCT05139810: OASIS-HAE: a study to evaluate the safety and efficacy of donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in participants with hereditary angioedema (HAE). 6 March 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05139810. Accessed 13 May 2025."},{"key":"798_CR52","unstructured":"ClinicalTrials.gov. NCT06007677: a long-term study of STAR-0215 in participants with hereditary angioedema. 14 March 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06007677. Accessed 13 May 2025."},{"issue":"1","key":"798_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health"},{"key":"798_CR54","volume-title":"Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques","author":"W Kuhfeld","year":"2010","unstructured":"Kuhfeld W. Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques. Cary, NC: SAS Institute Inc.; 2010."},{"issue":"4","key":"798_CR55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2307\/3151882","volume":"31","author":"WF Kuhfeld","year":"1994","unstructured":"Kuhfeld WF, Tobias RD, Garratt M. Efficient experimental design with marketing research applications. J Mark Res. 1994;31(4):545\u201357. https:\/\/doi.org\/10.2307\/3151882.","journal-title":"J Mark Res"},{"issue":"5","key":"798_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373\u201384. https:\/\/doi.org\/10.1007\/s40271-015-0118-z.","journal-title":"Patient"},{"issue":"4","key":"798_CR57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health"},{"key":"798_CR58","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511610356","volume-title":"Applied choice analysis: a primer","author":"D Hensher","year":"2005","unstructured":"Hensher D, Rose J, Greene W. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005."},{"issue":"2","key":"798_CR59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/biomet\/76.2.297","volume":"76","author":"CM Hurvich","year":"1989","unstructured":"Hurvich CM, Tsai C-L. Regression and time series model selection in small samples. Biometrika. 1989;76(2):297\u2013307. https:\/\/doi.org\/10.1093\/biomet\/76.2.297.","journal-title":"Biometrika"},{"key":"798_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/0471721182","volume-title":"Finite mixture models","author":"G McLachlan","year":"2000","unstructured":"McLachlan G, Peel D. Finite mixture models. New York, NY: John Wiley & Sons; 2000."},{"key":"798_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-4651-1","volume-title":"Market segmentation","author":"M Wedel","year":"2000","unstructured":"Wedel M, Kamakura WA. Market segmentation. 2nd ed. New York (NY): Springer; 2000.","edition":"2"},{"issue":"6","key":"798_CR62","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","volume":"8","author":"K Weller","year":"2020","unstructured":"Weller K, Donoso T, Magerl M, Aygoren-Pursun E, Staubach P, Martinez-Saguer I, et al. Validation of the Angioedema Control Test (AECT): a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract. 2020;8(6):2050-7.e4. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.038.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"798_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","volume":"10","author":"D Geba","year":"2021","unstructured":"Geba D, Mohd Sani J, Gascon M, Hahn R, Aggarwal K, Rosselli J. Hereditary angioedema patients would prefer newer-generation oral prophylaxis. J Drug Assess. 2021;10(1):51\u20136. https:\/\/doi.org\/10.1080\/21556660.2020.1863699.","journal-title":"J Drug Assess"},{"key":"798_CR64","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5414\/ALX02532E","volume":"8","author":"M Fasshauer","year":"2024","unstructured":"Fasshauer M, Wedi B. Hereditary angioedema (HAE) in children and adolescents: new treatment options. Allergol Select. 2024;8:336\u201345. https:\/\/doi.org\/10.5414\/ALX02532E.","journal-title":"Allergol Select"},{"key":"798_CR65","unstructured":"Andembry PI. CSL Behring LLC. Andembry (garadacimab-gxii) injection. June 2025. Available from: https:\/\/labeling.cslbehring.com\/PI\/US\/Andembry\/EN\/Andembry-Prescribing-Information.pdf. Accessed 29 Jul 2025."},{"issue":"10","key":"798_CR66","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","volume":"29","author":"MP Ho","year":"2015","unstructured":"Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984\u201393. https:\/\/doi.org\/10.1007\/s00464-014-4044-2.","journal-title":"Surg Endosc"},{"issue":"2","key":"798_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang JC, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22(2):157\u201360. https:\/\/doi.org\/10.1016\/j.jval.2018.07.876.","journal-title":"Value Health"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00798-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:47Z","timestamp":1777387547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00798-8","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cannon Kent and Caroline M. Vass are full-time employees of RTI Health Solutions, an independent non-profit research organization, which was retained by Ionis Pharmaceuticals to conduct the research that is the subject of this article. Their compensation is unconnected to the studies on which they work. Carol Mansfield was an employee of RTI Health Solutions when the study was conducted. Kathleen F. Villa, Aaron Yarlas, James A.\u00a0Ruggles, and Laura Bordone are employees of Ionis Pharmaceuticals and may hold shares and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the USA and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from the publication of this article.\u00a0For additional information, visit\u00a0\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"KFV, CM, AY, JAR, LB, CK, and CMV each made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}